Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial.

Authors:
Yang X; He Z; Yuan L; Huang W; Li D and 4 more

Journal:
BMC Endocr Disord

Publication Year: 2023

DOI:
10.1186/s12902-023-01461-9

PMCID:
PMC10563270

PMID:
37814256

Journal Information

Full Title: BMC Endocr Disord

Abbreviation: BMC Endocr Disord

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Endocrinology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Competing interestsThe authors declare no competing interests. Ethics approval and consent to participateThis study has been approved by the Medical Ethics Committee of the Jiangsu Hospital of Integrated Traditional Chinese and Western Medicine (2021-LWKYZ-002) according to the Medical Research Involving Human Subjects Act and the standards of Good Clinical Practice. Written informed consent will be obtained from all participants prior to study participation. Consent to publishNot applicable. Competing interests The authors declare no competing interests."

Evidence found in paper:

"Funding The 16th batch of “Six Talent Peak” projects in Jiangsu Province of China (WSN-035)."

Evidence found in paper:

"Trial registration ChiCTR2100043770(February 28, 2021)."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025